Literature DB >> 28570758

Variation in use of postoperative chemoradiation following surgery for T1 and T2 oropharyngeal squamous cell carcinoma; National Cancer Database.

Benjamin R Roman1, Shrujal S Baxi1, Jennifer R Cracchiolo1, Timothy J Blackwell1, David G Pfister1, Sean McBride1, Ian Ganly1, Jatin P Shah1, Snehal G Patel1, Luc G Morris1, Marc A Cohen1.   

Abstract

BACKGROUND AND OBJECTIVES: Primary surgical treatment of patients with early T-classification (T1-T2) oropharyngeal squamous cell carcinoma (OPSCC) has increased. We sought to determine how often these patients receive postoperative chemoradiation (CRT).
METHODS: Patients with T1-T2 OPSCC in the National Cancer Database who underwent primary surgery were evaluated for receipt of postoperative CRT. Postoperative CRT use was examined among patients with high risk factors (positive margins and/or extracapsular spread [ECS]), intermediate risk factors (negative margins, no ECS, and either pT3-4 and/or N2-N3), and no apparent risk factors.
RESULTS: Of 4833 patients with T1-T2 OPSCC who underwent primary surgery, 43% had high risk pathologic factors, of whom only 63% received postoperative CRT. Another 31% had no apparent risk factors, of whom 16% nonetheless received postoperative CRT. On multivariable analysis, in addition to tumor and demographic factors, patients treated at community hospitals were more likely to receive postoperative CRT (O.R. 1.41 C.I. 1.18-1.87, P = 0.001).
CONCLUSIONS: Variation in postoperative CRT use indicates a lack of consensus and/or knowledge about its benefits and indications. Usage of postoperative CRT regardless of pathologic risk factors suggests an area where future efforts at implementation of best practices may be targeted.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  HPV-related oropharyngeal squamous cell carcinoma (OPSCC); National Comprehensive Cancer Network (NCCN) guidelines; adjuvant chemoradiation (postoperative CRT); hospital-level variation; pathologic risk factors

Mesh:

Year:  2017        PMID: 28570758      PMCID: PMC5533641          DOI: 10.1002/jso.24674

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  21 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  A shifting paradigm for patients with head and neck cancer: transoral robotic surgery (TORS).

Authors:  Amy Y Chen
Journal:  Oncology (Williston Park)       Date:  2010-10       Impact factor: 2.990

Review 3.  The role of surgery for HPV-associated head and neck cancer.

Authors:  Wojciech K Mydlarz; Jason Y K Chan; Jeremy D Richmon
Journal:  Oral Oncol       Date:  2014-10-30       Impact factor: 5.337

4.  Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status.

Authors:  Jessica H Maxwell; Robert L Ferris; William Gooding; Diana Cunningham; Vikas Mehta; Seungwon Kim; Eugene N Myers; Jonas Johnson; Simion Chiosea
Journal:  Cancer       Date:  2013-06-24       Impact factor: 6.860

5.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

6.  Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base.

Authors:  Jennifer R Cracchiolo; Shrujal S Baxi; Luc G Morris; Ian Ganly; Snehal G Patel; Marc A Cohen; Benjamin R Roman
Journal:  Cancer       Date:  2016-03-11       Impact factor: 6.860

7.  Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.

Authors:  Bruce H Haughey; Parul Sinha
Journal:  Laryngoscope       Date:  2012-09       Impact factor: 3.325

Review 8.  Using the NCDB for cancer care improvement: an introduction to available quality assessment tools.

Authors:  Mehul V Raval; Karl Y Bilimoria; Andrew K Stewart; David J Bentrem; Clifford Y Ko
Journal:  J Surg Oncol       Date:  2009-06-15       Impact factor: 3.454

9.  How can we improve guideline use? A conceptual framework of implementability.

Authors:  Anna R Gagliardi; Melissa C Brouwers; Valerie A Palda; Louise Lemieux-Charles; Jeremy M Grimshaw
Journal:  Implement Sci       Date:  2011-03-22       Impact factor: 7.327

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more
  3 in total

1.  pN status predicts outcomes in surgically treated pT1-pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study.

Authors:  Xu Qian; Branko Sinikovic; Frank Schreiber; Sebastian Ochsenreither; Konrad Klinghammer; Barbara Wollenberg; Andreas M Kaufmann; Andreas E Albers
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-29       Impact factor: 2.503

2.  Disparities and guideline adherence for HPV testing among patients with oropharyngeal squamous cell carcinoma, NCDB, and SEER.

Authors:  Solomon Husain; Shivangi Lohia; Valentina Petkov; Timothy Blackwell; Samuel Swisher-McClure; Aviram Mizrachi; Luc G Morris; Marc A Cohen; Richard J Wong; Benjamin R Roman
Journal:  Head Neck       Date:  2021-04-13       Impact factor: 3.821

3.  Benefit from surgery with additional radiotherapy in N1 head and neck cancer at the time of IMRT: A population-based study on recent developments.

Authors:  Christoph Evers; Christian Ostheimer; Frank Sieker; Dirk Vordermark; Daniel Medenwald
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.